{"description":"Only immediately reportable Serious Adverse Events (SAE) \\& Venous thrombolytic event (VTE) were captured for the purpose of this study.","eventGroups":[{"description":"Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels\n\nepoetin alfa: Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.","id":"EG000","otherNumAffected":3,"otherNumAtRisk":31,"seriousNumAffected":0,"seriousNumAtRisk":31,"title":"Epoetin Alfa - 80,000 U sc"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31,"numEvents":3}],"term":"Venous Thromboembolic Event (VTE)"}],"timeFrame":"AE data highlights development of VTEs in patients receiving one of the following: 1. lenalidomide, high dose dexamethasone & Aspirin 325mg daily 2. thalidomide & doxil based therapy with aspirin 81mg daily 3. cyclophosphamide & prednisone without VTE"}